LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To help determine the cause of unexplained excessive or repeated episodes of bleeding, to diagnose von Willebrand disease (VWD), and to distinguish between different types of VWD
When you have a personal or family history of heavy, prolonged, and/or spontaneous bleeding; when your healthcare provider suspects that you may have a bleeding disorder
A blood sample drawn from a vein in your arm
Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together, and in sequence, to stop bleeding within the body. VWF testing measures the amount of the protein present in blood and determines how well the protein functions.
Normally, when a blood vessel is damaged and bleeding begins, VWF forms an adhesive bridge between activated cell fragments called platelets and the injury site. This is followed by the clumping (aggregation) of platelets at the site and a series of actions referred to as activation of the coagulation cascade, resulting in the formation of a stable blood clot.
VWF further affects clotting by influencing the availability of coagulation factor VIII. VWF carries factor VIII in the blood, increases its half-life, and releases it as necessary. If the amount of functional VWF is insufficient, then platelet adherence and aggregation are affected, levels of factor VIII could be decreased, blood clot formation takes longer, and therefore bleeding is prolonged. This deficiency causes a condition referred to as von Willebrand disease (VWD).
VWD is the most common inherited bleeding disorder. It is a group of conditions associated with prolonged bleeding due to deficient and/or defective VWF. VWD is separated into different types and sub-types, including:
Rarely, VWD may be due to an acquired VWF deficiency, where there is no family or personal bleeding history up to the point when signs and symptoms develop.
Von Willebrand factor testing includes VWF antigen, which measures the amount of VWF, and VWF activity (also known as Ristocetin Cofactor), which evaluates the function of VWF. Some laboratories may offer a panel that includes both of these tests along with a factor VIII activity test.
Von Willebrand factor (VWF) testing is used to investigate excessive or recurrent bleeding episodes or a personal or family history of excessive bleeding. Testing is used to help diagnose von Willebrand disease (VWD) and distinguish between the various types of VWD.
Two types of tests may be used:
These tests may be ordered by themselves or along with a coagulation factor VIII activity test and following other bleeding disorder tests, such as a complete blood count (CBC), platelet count, platelet function tests (e.g., platelet aggregation, etc.), PT (prothrombin time), and/or PTT (partial thromboplastin time).
Other tests may be ordered following VWF testing for more information and to distinguish between subtypes. These may include:
VWF testing is ordered after initial screening tests for a bleeding disorder (such as platelet function tests, PT, PTT) have been performed to investigate someone's personal or family history of excessive or recurrent bleeding episodes. The signs and symptoms that may prompt testing vary depending on the type of VWD an individual has and may include:
VWF tests may intermittently be normal in patients with VWD and should be repeated when they are initially normal but suspicions of VWD remain high. Repeat testing should be done after more than 2 weeks to confirm or exclude the diagnosis.
When VWF testing suggests VWD, additional testing may be performed to determine which subtype the person has.
Interpretation of VWF test results can be challenging and may require consultation with a doctor who specializes in bleeding disorders, such as a hematologist or coagulation specialist, especially when determining subtypes. People who have mild VWD may have normal VWF antigen and VWF activity test results, and people who do not have VWD may have moderately decreased test results.
In a person with normal or near normal bleeding disorder screening test results, a significantly decreased VWF antigen test suggests that the person tested has a quantitative VWF deficiency and may have Type 1 VWD or, more rarely, may have acquired VWD.
Using VWF antigen results along with the VWF activity (Ristocetin Cofactor) and factor VIII coagulant activity give the optimal combination for diagnosis and management. If the VWF antigen test is normal or nearly normal and the VWF activity (Ristocetin Cofactor) is decreased, then the person may have Type 2 VWD. Further testing (e.g., VWF multimeric analysis) will be required to determine which subtype is present.
If no or very little VWF and factor VIII are present, then the person may have Type 3 VWD. This will typically be seen in a child who experiences bleeding episodes early in life. It may appear to be due (or actually be due) to hemophilia A, a factor VIII deficiency bleeding disorder that affects males.
Increased concentrations of VWF antigen and VWF activity are not considered diagnostic. VWF is one of many acute phase reactants. This means that levels will be temporarily increased with infections, inflammation, trauma, and with physical and emotional stressors. They are also increased with pregnancy and with the use of estrogen medications such as oral contraceptives.
VWF testing must be performed in a laboratory and is often sent to a reference laboratory. It requires specialized equipment and interpretation.
It is possible, but many women who experience heavy bleeding during menstruation do not have VWD.
Yes. Some people experience no or few symptoms, even though they have quantitative or qualitative VWF deficiencies.
Yes. This is important information for your healthcare providers, including your dentist, to have. They will need to plan ahead for any surgeries, childbirths, or dental procedures you may have.
Yes, there is treatment that can be given intermittently, primarily before procedures that may trigger bleeding. There is a medication called desmopressin (DDAVP) that promotes the release of VWF in some people with VWD. In addition, recombinant von Willebrand factor was approved by the US Food and Drug Administration (FDA) in December 2015. There are also VWF/FVIII concentrate replacement therapies when the recombinant is ineffective or contraindicated and there are other non-VWF related measures that can be taken to control bleeding.
Yes, a deficiency in VWF may be due to another disease or condition, where there is no family or personal bleeding history up to the point when signs and symptoms develop, but this rarely occurs. It is sometimes seen in people with:
• Conditions that cause the breakdown of VWF, such as increased pressure in the arteries leading from the heart to the lungs (pulmonary hypertension) and structural defects of the heart (e.g., aortic valve stenosis)
• Lymphoma, myeloma, or autoimmune disorders (such as lupus) that cause the production of VWF antibodies
• Myeloproliferative neoplasms associated with increased platelet production that cause increased binding of VWF to platelets
• Hypothyroidism, which can decrease VWF production
• Wilms tumor and other disorders that bind to VWF and remove it from the blood
• Certain medications such as valproic acid, ciprofloxacin, hetastarch
A person's ABO blood group affects VWF concentrations. People with type O blood have VWF levels that are up to 25% lower than those with other blood types.
Measuring levels of other acute phase reactants such as CRP and fibrinogen may be helpful if VWF levels are borderline normal. For example, a borderline normal VWF with significantly high CRP and/or fibrinogen may suggest VWD.
VWF is produced by megakaryocytes and by the endothelial cells that line blood vessels. It is released by platelets and endothelial cells as needed.
Sources Used in Current Review
2018 Review completed by Rita Khoury, MD, DABCC, FACB, Laboratory Director, Aculabs, Inc.
Stuijver DJ; Piantanida E; van Zaane B; Galli L; Romualdi E; Tanda ML; Meijers JC; Büller HR; Gerdes VE; Squizzato A. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. Haemophilia. 2014; 20(3):326-32
Waldow HC; Westhoff-Bleck M; Widera C; Templin C; von Depka M. Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol. 2014; 176(3):739-45 (ISSN: 1874-1754)
Roberts JC; Flood VH. Laboratory diagnosis of von Willebrand disease. Int J Lab Hematol. 2015; 37 Suppl 1:11-7 (ISSN: 1751-553X)
Hayward CP; Moffat KA; Graf L. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges. Int J Lab Hematol. 2014; 36(3):334-40 (ISSN: 1751-553X)
Tosetto A. Bleeding Assessment Tools: Limits and Advantages for the Diagnosis and Prognosis of Inherited Bleeding Disorders. Semin Thromb Hemost. 2016 Jul. 42 (5):463-70.
Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015 Oct 22. 126 (17):2038-46.
[Guideline] Laffan MA, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014 Aug 12.
Sources Used in Previous Reviews
Yawn, B. et. al.(2009 December 1) Diagnosis and Management of Von Willebrand Disease: Guidelines for Primary Care. American Family Physician [On-line information]. Available online at http://www.aafp.org/afp/2009/1201/p1261.html. Accessed February 2010.
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 280.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 1144-1145.
Rodgers, III, G. and Smock, K. (Updated 2009 August). von Willebrand Disease – vWD. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/vWD.html?client_ID=LTD. Accessed February 2010.
(Revised 2009 May). What Is von Willebrand Disease? National Heart Lung and Blood Institute [On-line information]. Available online at http://www.nhlbi.nih.gov/health/dci/Diseases/vWD/vWD_WhatIs.html. Accessed February 2010.
Geil, J. (Updated 2009 May 21). Von Willebrand Disease. eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/959825-overview. Accessed February 2010.
Goodeve, A. and James, P. (2009 June 4). von Willebrand Disease. GeneReviews [On-line information]. Available online at http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene∂=von-willebrand. Accessed February 2010.
Mayo Clinic Staff (2009 February 7). Von Willebrand disease. MayoClinic.com [On-line information]. Available online at http://www.mayoclinic.com/health/von-willebrand-disease/DS00903. Accessed February 2010.
George, J. (Revised 2009 May). Von Willebrand's Disease. Merck Manual for Healthcare Professionals [On-line information]. Available online at http://www.merck.com/mmpe/sec11/ch133/ch133h.html#sec11-ch133-ch133h-410. Accessed February 2010.
Grund, S. (Updated 2008 March 21). Von Willebrand disease. MedlinePlus Medical Encylopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/000544.htm. Accessed February 2010.
Link, R. (Updated 2009 March 4). Bleeding Disorders, Frequently Asked Questions. Womenshealth.gov [On-line information]. Available online at http://www.womenshealth.gov/faq/bleeding-disorders.cfm. Accessed February 2010.
Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 236-237.
Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2007 pp 760-762.
Pollak, E. (Updated 2012 April 6) von Willebrand Disease. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/206996-overview. Accessed November 2013.
Medscape Editorial Staff (Updated 2012 October 1). von Willebrand Factor Antigen (Factor VIII:R Antigen) Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/2086366-overview. Accessed November 2013.
(2011 June 1). What Is von Willebrand Disease? National Heart Lung and Blood Institute [On-line information]. Available online at http://www.nhlbi.nih.gov/health/health-topics/topics/vwd/. Accessed November 2013.
Heikal, N. et. al. (Updated 2013 October). von Willebrand Disease – VWD. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/VWD.html. Accessed November 2013.
Gersten, T. (Updated 2012 February 16). Von Willebrand disease. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/000544.htm. Accessed November 2013.
(© 1995–2013). von Willebrand Profile. Mayo Clinic Mayo Medical Laboratory [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/83099. Accessed November 2013.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 277.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 277-279.
McPherson, R. and Pincus, M. (© 2011). Henry's Clinical Diagnosis and Management by Laboratory Methods 22nd Edition: Elsevier Saunders, Philadelphia, PA. Pp 816-819.
(Updated 1, 2011) National Heart Lung and Blood Institute. What is von Willebrand Disease? Available online at http://www.nhlbi.nih.gov/health/health-topics/topics/vwd/. Accessed November 2013.